Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. How important is quality of life?

Eur J Health Econ. 2004 Jun;5(2):188-9. doi: 10.1007/s10198-004-0226-5.
No abstract available

Publication types

  • Comparative Study

MeSH terms

  • Antimetabolites, Antineoplastic / economics*
  • Antimetabolites, Antineoplastic / therapeutic use
  • Clinical Trials as Topic
  • Cost-Benefit Analysis
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / economics*
  • Deoxycytidine / therapeutic use
  • Gemcitabine
  • Humans
  • Pancreatic Neoplasms / drug therapy
  • Pancreatic Neoplasms / economics*
  • Quality of Life*
  • Quality-Adjusted Life Years
  • United Kingdom

Substances

  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Gemcitabine